Soluble angiotensin-converting enzyme 2 as a prognostic biomarker for disease progression in patients infected with SARS-CoV-2

Data Availability

The study was conducted in accordance with applicable regulations. Ethical approval was provided by the Research Ethics Committee for Drug Research of the Vall d'Hebron University Hospital (Barcelona, Spain). An exemption from obtaining patient informed consent was granted by the Research Ethics Committee due to the health emergency presented by the COVID-19 pandemic. Therefore, participants of this study did not give consent for their data to be shared with additional third parties. For more information on the study and data sharing, qualified researchers may contact the corresponding author Francisco Rodriguez-Frias (frarodri{at}gmail.com).